AIM OF THE STUDY: To assess the @entity620 (AA) in the follicular fluid in @entity1 treated by in vitro fertilization and embryonic transfer levels (IVF/ET) and to analyse the influence of @entity620 supplementation on the results of @entity249 treatment. TYPE OF THE STUDY: Prospective study in @entity1 treated by IVF/ET. METHODS: The influence of @entity620 supplementation on the outcome of @entity249 treatment in the assisted reproduction programme in 76 @entity1 (38 of them smokers, 38 non-smokers) was studied. Half the @entity1 (19 smokers and 19 non-smokers) were administered @entity620 in daily doses of 500 mg in so-called pellets allowing for gradual release over 8 to 12 hours. The control group consisted of the same number of smokers and non-smokers. In all the @entity1 , @entity620 levels were determined in two urine samples (prior to supplementation and at follicle retrieval) and in follicular fluid by means of a colorimetric method. Ovarian response to hormonal stimulation with gonadotropins (hMG, FSH) at a dosage of 150-225 IU per day combined with @entity1176 analogues in the short (buserelin) or long ( @entity19040 ) protocols, and 5,000-10,000 IU of @entity1 chorionic gonadotropin was evaluated based on the number of follicles created and number of retrieved oocytes. Fertilisation was assessed, based on the number of successfully fertilised oocytes (fertilisation rate) and based on the number of cultivated embryos. The success of the @entity249 treatment was evaluated based on the number of pregnancies. RESULTS: @entity620 levels in follicles were significantly higher (p < 0.001) in @entity1 with @entity620 supplementation than in the control group (8.98 +/- 5.09 vs. 5.04 +/- 2.85 mg/l). The administration of @entity620 during the period of hormonal stimulation showed a statistically insignificant impact in terms of the higher number of pregnancies (34.2% vs. 23.7%). @entity2221 supplementation had a greater impact on the number of pregnancies in the non-smokers' group (57.9% vs. 31.6%). The pregnancy rate was significantly higher (p < 0.01) in non-smoking @entity1 than in smokers--44.7% vs. 13.2%, which appears to be a reason for asking @entity1 to cease smoking prior to @entity249 treatment.

@entity620 and XXXX treatment.

@entity1 :: ('9606', 'Species') :: ['women', 'human'] @entity19040 :: ('MESH:D017329', 'Chemical') :: ['triptorelin'] @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility'] @entity620 :: ('MESH:D001205', 'Chemical') :: ['Ascorbic acid', 'vitamin C', 'ascorbic acid'] @entity1176 :: ('MESH:D007987', 'Chemical') :: ['GnRH'] @entity2221 :: ('CHEBI:33229', 'Chemical') :: ['Vitamin']
@entity249 :: (MESH:D007246,Disease) :: ['infertility']
